secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001558370-24-008210
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune Q1 net loss $48.5M; afami-cel PDUFA Aug 4; secures $125M debt
-------------------------------------------------------------------------

- Revenue $5.7M (down from $47.6M YoY); net loss $48.5M vs profit $1.0M in Q1 2023.
- FDA PDUFA date for afami-cel BLA set for August 4, 2024; GMP and GCP inspections ongoing.
- Secured up to $125M debt financing with Hercules Capital; first $25M available at close.
- Lete-cel pivotal trial IGNYTE-ESO met primary efficacy endpoint; full analysis expected late 2024.
- Cash and cash equivalents $140.7M; cash runway extended into late 2025 with anticipated afami-cel revenues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/0001558370-24-008210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/adap-20240515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer